[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ITTO20060239A1 - Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare - Google Patents

Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare

Info

Publication number
ITTO20060239A1
ITTO20060239A1 IT000239A ITTO20060239A ITTO20060239A1 IT TO20060239 A1 ITTO20060239 A1 IT TO20060239A1 IT 000239 A IT000239 A IT 000239A IT TO20060239 A ITTO20060239 A IT TO20060239A IT TO20060239 A1 ITTO20060239 A1 IT TO20060239A1
Authority
IT
Italy
Prior art keywords
formulation
oral administration
health effects
activity
lowering
Prior art date
Application number
IT000239A
Other languages
English (en)
Inventor
Angelo Luigi Rovati
Paolo Senin
Ivo Setnikar
Original Assignee
Rotthapharm S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rotthapharm S P A filed Critical Rotthapharm S P A
Priority to IT000239A priority Critical patent/ITTO20060239A1/it
Priority to AT07735308T priority patent/ATE547098T1/de
Priority to PCT/IB2007/051109 priority patent/WO2007113748A1/en
Priority to DK07735308.4T priority patent/DK2007429T3/da
Priority to PT07735308T priority patent/PT2007429E/pt
Priority to ES07735308T priority patent/ES2382115T3/es
Priority to PL07735308T priority patent/PL2007429T3/pl
Priority to EP07735308A priority patent/EP2007429B1/en
Priority to US12/295,616 priority patent/US9623108B2/en
Publication of ITTO20060239A1 publication Critical patent/ITTO20060239A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IT000239A 2006-03-30 2006-03-30 Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare ITTO20060239A1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT000239A ITTO20060239A1 (it) 2006-03-30 2006-03-30 Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare
AT07735308T ATE547098T1 (de) 2006-03-30 2007-03-29 Orale formulierung mit vorteilhaften kardiovaskulären wirkungen und berberin-gehalt
PCT/IB2007/051109 WO2007113748A1 (en) 2006-03-30 2007-03-29 Oral formulation with beneficial cardiovascular effects, comprising berberine
DK07735308.4T DK2007429T3 (da) 2006-03-30 2007-03-29 Oralt præparat med gavnlige cardiovaskulære virkninger indeholdende berberin
PT07735308T PT2007429E (pt) 2006-03-30 2007-03-29 Formulação oral com efeitos cardiovasculares benéficos, compreendendo berberina
ES07735308T ES2382115T3 (es) 2006-03-30 2007-03-29 Formulación oral con efectos cardiovasculares beneficiosos, que comprende berberina
PL07735308T PL2007429T3 (pl) 2006-03-30 2007-03-29 Doustna kompozycja o korzystnym działaniu sercowo-naczyniowym, zawierająca berberynę
EP07735308A EP2007429B1 (en) 2006-03-30 2007-03-29 Oral formulation with beneficial cardiovascular effects, comprising berberine
US12/295,616 US9623108B2 (en) 2006-03-30 2007-03-29 Formulation for oral administration with beneficial effects on the cardiovascular system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000239A ITTO20060239A1 (it) 2006-03-30 2006-03-30 Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare

Publications (1)

Publication Number Publication Date
ITTO20060239A1 true ITTO20060239A1 (it) 2007-09-30

Family

ID=38421558

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000239A ITTO20060239A1 (it) 2006-03-30 2006-03-30 Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare

Country Status (9)

Country Link
US (1) US9623108B2 (it)
EP (1) EP2007429B1 (it)
AT (1) ATE547098T1 (it)
DK (1) DK2007429T3 (it)
ES (1) ES2382115T3 (it)
IT (1) ITTO20060239A1 (it)
PL (1) PL2007429T3 (it)
PT (1) PT2007429E (it)
WO (1) WO2007113748A1 (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110670B2 (en) 2006-05-19 2012-02-07 Ls9, Inc. Enhanced production of fatty acid derivatives
US20100242345A1 (en) 2006-05-19 2010-09-30 LS9, Inc Production of fatty acids & derivatives thereof
WO2009140696A2 (en) 2008-05-16 2009-11-19 Ls9, Inc. Methods and compositions for producing hydrocarbons
ITMI20081403A1 (it) 2008-07-29 2010-01-30 Velleja Res Srl Composizioni comprendenti berberina e/o suoi analoghi o estratti che la contengano, per la prevenzione e il trattamento delle alterazioni del quadro lipidico e glucidico
US8999686B2 (en) * 2008-10-28 2015-04-07 REG Life Sciences, LLC Methods and compositions for producing fatty alcohols
WO2010104595A1 (en) * 2009-03-11 2010-09-16 Xintria Pharmaceutical Corporation, Inc. Methods and compositions for the treatment of metabolic and cardiovascular disorders
CN102459622B (zh) 2009-04-27 2020-08-18 基因组股份公司 脂肪酸酯的产生
FR2950061B1 (fr) 2009-09-11 2013-12-20 Coatex Sas Monomeres associatifs a base de polycosanols, epaississants associatifs correspondants et leurs utilisations
KR101307051B1 (ko) 2011-05-20 2013-09-11 강릉원주대학교산학협력단 미세조류 단백질 가수분해물을 포함하는 콜레스테롤 강하용 조성물
ITMI20121696A1 (it) * 2012-10-09 2014-04-10 Ddf Group S A S Composizioni per il trattamento delle iperlipidemie
ITMI20130241A1 (it) * 2013-02-21 2014-08-22 Andrea Rondi Composizione per il trattamento di disordini metabolici
ITUB20150541A1 (it) 2015-03-03 2016-09-03 Acraf Composizione comprendente sostanze e/o estratti naturali
ES2846909T3 (es) 2015-03-16 2021-07-30 Natures Sunshine Products Inc Fitocomplejos que muestran múltiples actividades antioxidantes sinérgicas
EP3117825A1 (en) * 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
IT201900020300A1 (it) * 2019-11-04 2021-05-04 Alesco Srl Uso di berberina sucrosomiale® e sue composizioni nel trattamento di dislipidemie
WO2021090214A2 (en) * 2019-11-04 2021-05-14 Alesco S.R.L. Sucrosomial® berberine, its compositions and their use
IT201900020316A1 (it) * 2019-11-04 2021-05-04 Alesco Srl Uso di berberina sucrosomiale® e sue composizioni nel trattamento di alterazioni del metabolismo glucidico
IT201900020290A1 (it) * 2019-11-04 2021-05-04 Alesco Srl Berberina sucrosomiale®, sue composizioni e loro uso
IT202200008534A1 (it) * 2022-04-29 2023-10-29 Neilos S R L “Composizione nutraceutica o farmaceutica per la salute cardiovascolare”
IT202200008537A1 (it) * 2022-04-29 2023-10-29 Neilos S R L “Composizione nutraceutica o farmaceutica per la salute cardiovascolare”
DE202023106947U1 (de) 2023-11-23 2024-01-10 Supett Laboratories Limited Zusammensetzung umfassend Panthenol, PQQ und Quercetin zur Vorbeugung von Herzkrankheiten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952393A (en) 1998-02-12 1999-09-14 Sorkin, Jr.; Harlan Lee Composition for reducing serum cholesterol levels
US6436406B1 (en) 2000-06-15 2002-08-20 A. Glenn Braswell Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis
AUPR510001A0 (en) 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
US20030054978A1 (en) 2001-08-31 2003-03-20 Babish John G. Arginine compositions for coordinate modification of multiple cardiovascular risk factors
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
ITTO20040682A1 (it) * 2004-10-07 2005-01-07 Rottapharm S R L Formulazione per somministrazione orale avente un effetto salutistico sull'apparato cardiovascolare

Also Published As

Publication number Publication date
ATE547098T1 (de) 2012-03-15
PL2007429T3 (pl) 2012-07-31
US20090136469A1 (en) 2009-05-28
US9623108B2 (en) 2017-04-18
EP2007429B1 (en) 2012-02-29
PT2007429E (pt) 2012-04-12
ES2382115T3 (es) 2012-06-05
DK2007429T3 (da) 2012-05-29
WO2007113748A1 (en) 2007-10-11
EP2007429A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
ITTO20060239A1 (it) Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
EA201291410A1 (ru) Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EP2349279A4 (en) MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
EA201001285A1 (ru) Применение 25-oh d3 для воздействия на физиологию мышц человека
MX365313B (es) Composición farmacéutica oral que comprende a,a,a-trifluorotimidin a y clorhidrato de 5-cloro-6-(2-iminopirrolidina-1-il)metil-2,4(1h ,3h)-pirimidina diona.
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX355885B (es) Composición farmacéutica de administración oral.
CY1108314T1 (el) Σκευασμα για στοματικη χορηγηση εχοντας μια δραση που προαγει την υγεια επι του καρδιαγγειακου συστηματος
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
AU2012345659A8 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
CL2012003250A1 (es) Uso de un galactolipido en combinacion con acido ascorbico y/o un derivado del mismo que sirve para proteger una composicion contra la oxidacion; metodo para la preparacion de la composicion, composicion; y producto.
CY1111361T1 (el) Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
WO2015021387A3 (en) Formulations for control and prevention of periodontal and perimplant diseases and other diseases and conditions of the mouth, and supra and sub-gingival delivery methods and systems for such formulations
WO2013173803A3 (en) Formulations of amoxicillin and clavulanate potassium and methods for using same
WO2011092655A3 (en) Mentha suaveolens essential oil and therapeutic activities thereof
IT1406221B1 (it) Composizione contenente resveratrolo l/triptofano acido l/aspartico e vitamina b3 (nad+) per l'impiego in campo farmaceutico nutrizionale e cosmetico